Drug Insight: translating evidence on statin therapy into clinical benefits

[1]  A. Demchuk,et al.  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial , 2007, The Lancet Neurology.

[2]  A. Folsom,et al.  Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective Study , 2007, Stroke.

[3]  M. A. Moro,et al.  Statin treatment withdrawal in ischemic stroke , 2007, Neurology.

[4]  Della A. Campbell.  Secondary Analysis , 2007, Orthopedic nursing.

[5]  G. Duckwiler,et al.  Statin enhancement of collateralization in acute stroke , 2007, Neurology.

[6]  J. Saver,et al.  High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment , 2007, Stroke.

[7]  Y. Sasaguri,et al.  Statin Treatment Upregulates Vascular Neuronal Nitric Oxide Synthase Through Akt/NF-&kgr;B Pathway , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Gotto,et al.  Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. , 2006, Journal of the American College of Cardiology.

[9]  L. Goldstein,et al.  Abstract 2985: Lipoprotein, Blood Pressure and Stroke Risk: Findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2006 .

[10]  M. Endres,et al.  Discontinuation of Statin Treatment in Stroke Patients , 2006, Stroke.

[11]  D. Liebeskind,et al.  Achieving target cholesterol goals after stroke: is in-hospital statin initiation the key? , 2006, Archives of neurology.

[12]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[13]  J. Switzer,et al.  Statins in stroke: prevention, protection and recovery , 2006, Expert review of neurotherapeutics.

[14]  B. Ovbiagele,et al.  Multimodality Stroke Prevention , 2006, The neurologist.

[15]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[16]  M. McGowan.  There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients , 2004, Circulation.

[17]  B. Coull.  Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? , 2004, Stroke.

[18]  J. Cleeman,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Müllner,et al.  Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events , 2004, Journal of the Neurological Sciences.

[20]  S. Warach,et al.  Rising statin use and effect on ischemic stroke outcome , 2004, BMC medicine.

[21]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[22]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[23]  A. Algra,et al.  Risk Factors for Intracerebral Hemorrhage in the General Population: A Systematic Review , 2003, Stroke.

[24]  J. Corvol,et al.  Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. , 2003, Archives of internal medicine.

[25]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[26]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[27]  M. Hecker,et al.  3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[29]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[30]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[31]  R. Rosenson,et al.  Biological basis for statin therapy in stroke prevention. , 2000, Current opinion in neurology.

[32]  N. Delanty,et al.  Neuroprotective properties of statins in cerebral ischemia and stroke. , 1999, Stroke.

[33]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[34]  N. Delanty,et al.  Vascular effects of statins in stroke. , 1997, Stroke.

[35]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[36]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[37]  J. Cutler,et al.  Risk factors for death from different types of stroke , 1993 .

[38]  J. Provencio.  High-Dose Atorvastatin after Stroke or Transient Ischemic Attack , 2007 .

[39]  HiroakiShimokawa,et al.  Statin Treatment Upregulates Vascular Neuronal Nitric Oxide Synthase Through Akt/NF-κB Pathway , 2007 .

[40]  G. Moneta.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions Heart , 2022 .

[41]  J. Saver,et al.  Expanding indications for statins in cerebral ischemia: a quantitative study. , 2005, Archives of neurology.

[42]  Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. , 2004, Stroke.

[43]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.

[44]  Burkhard Hornig,et al.  Endothelial function: a critical determinant in atherosclerosis? , 2004, Circulation.

[45]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[46]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[47]  J. Cutler,et al.  Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. , 1993, Annals of epidemiology.

[48]  Expanding indications , 1993 .

[49]  R. Collins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .